Does Group Health Cooperative (GHC) Cover Prolia?

What Prolia Is and Why Coverage Rules Are Stricter Than for Generic Drugs

Prolia is a RANK-ligand inhibitor, not a bisphosphonate. It works by binding RANKL and blocking osteoclast formation, which slows bone breakdown and raises bone mineral density (BMD) over time. The FDA approved denosumab in 2010 for postmenopausal women at high fracture risk, and has since extended labeling to men with osteoporosis, patients on long-term glucocorticoid therapy, and patients on androgen-deprivation or aromatase-inhibitor therapy for prostate or breast cancer [1].

Because Prolia carries a list price near $1,400 per injection, insurers including GHC plans place it on specialty or high-cost tiers. That placement triggers prior authorization (PA) protocols automatically. PA is not a punishment; it reflects formulary management designed to ensure the drug is used in patients most likely to benefit. The FREEDOM trial (N=7,808) demonstrated that denosumab reduced vertebral fracture risk by 68% and hip fracture risk by 40% at 36 months compared with placebo [2]. Those are compelling numbers, and most GHC clinical reviewers are familiar with them. The challenge is not proving Prolia works. It is proving that you specifically meet the plan's criteria on paper.

For most enrollees, GHC plans are administered or underwritten through partnerships with regional health systems and, in many markets, through Premera Blue Cross or Kaiser Permanente-affiliated networks, depending on the employer group or individual plan purchased. Always confirm which entity is actually processing your pharmacy or medical claims before submitting a PA request, because formulary criteria can differ between the carrier and the GHC-branded plan.

GHC Formulary Placement and What That Means for Your Cost-Share

Most GHC-aligned formularies place Prolia in a specialty tier, which carries the highest cost-sharing category. Depending on your specific plan document, that cost-share might be expressed as a percentage of the drug's allowed cost (commonly 20-33%) rather than a flat copay.

At an allowed cost of roughly $1,350 per injection (insurers negotiate below list price), a 25% coinsurance equals about $337 per injection or $675 per year before you hit your out-of-pocket maximum. Once you exceed your plan's out-of-pocket maximum, typically $4,000-$9,100 for an individual under ACA-compliant plans in 2024, the plan pays 100% of in-network covered costs for the rest of the benefit year [3].

Prolia is administered by a clinician and billed under the medical benefit (CPT 96372 for the injection, J0897 for the drug itself) rather than the pharmacy benefit in most clinical settings. That distinction matters. Medical-benefit cost-sharing rules may differ from pharmacy-benefit rules under your specific plan. A patient who expects a pharmacy copay of $75 may be surprised by a 20% medical coinsurance applied to a $1,350 drug charge. Checking both the pharmacy and medical sections of your Evidence of Coverage document is not optional if you want an accurate cost estimate.

Amgen's Prolia AMGIVA co-pay card program may reduce out-of-pocket costs for commercially insured patients to as little as $25 per injection, though it does not apply to federally funded programs such as Medicare or Medicaid [4].

Standard Prior Authorization Criteria GHC Reviewers Apply

Prior authorization for Prolia under GHC-aligned plans typically requires all of the following elements, though exact criteria appear in the plan's coverage determination guidelines and can change each January 1 benefit renewal.

Diagnosis confirmation. Your clinician must document a qualifying diagnosis: postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis (defined by the American College of Rheumatology as prednisone 5 mg/day or equivalent for 3 or more months), or bone loss secondary to hormone-ablation therapy for prostate or breast cancer [5].

Bone mineral density or fracture history. A DXA scan showing a T-score of -2.5 or below at the lumbar spine or hip, or a T-score between -1.0 and -2.5 with a 10-year major osteoporotic fracture probability at or above 20% (per FRAX), or a documented fragility fracture, typically satisfies this requirement. The National Osteoporosis Foundation's Clinician's Guide specifies these thresholds as treatment triggers [6].

Step therapy (bisphosphonate trial). Most GHC PA criteria require at least a 12-month trial of an oral bisphosphonate, commonly alendronate 70 mg weekly, with documented intolerance or therapeutic failure before Prolia will be approved as a first-line agent. Intolerance documentation should include specific symptoms such as esophageal irritation or severe musculoskeletal pain, the date they occurred, and the prescriber's clinical note confirming the medication was discontinued because of those symptoms.

Prescriber specialty. Some plan variants require or strongly prefer that the request originate from an endocrinologist, rheumatologist, or gynecologist with osteoporosis management experience rather than a primary care physician alone. If your PCP is submitting the PA, attaching a specialist consultation note strengthens the file significantly.

Treatment duration. Initial approvals are typically for 12 months (two injections). Renewal PA requires documentation of BMD response, ongoing qualifying diagnosis, and absence of hypocalcemia or other contraindications.

Step Therapy: What Counts as an Adequate Bisphosphonate Trial

Step therapy requires that a less expensive agent be tried first. For osteoporosis, that usually means alendronate (Fosamax) or risedronate (Actonel). Generic alendronate 70 mg weekly costs under $15 per month at most pharmacies, which is why plans default to it.

An adequate trial is generally 12 continuous months. However, several documented circumstances allow you to skip to Prolia directly. These include upper gastrointestinal disease (Barrett's esophagus, active esophagitis, documented GERD refractory to PPI therapy), inability to remain upright for 30 minutes after dosing, abnormal esophageal anatomy, chronic kidney disease with an eGFR below 35 mL/min/1.73 m2 (bisphosphonates carry a contraindication here), prior atypical femoral fracture on bisphosphonate therapy, or osteonecrosis of the jaw attributed to prior bisphosphonate use.

The 2022 American Association of Clinical Endocrinology (AACE) Postmenopausal Osteoporosis guidelines state: "Denosumab is appropriate as first-line therapy in patients with contraindications to bisphosphonates, including renal impairment." [7] That guideline language is your strongest asset when arguing for a step-therapy exemption. Submit the AACE guideline page alongside the PA form.

Bone metastasis from prostate or breast cancer is a separate FDA-approved indication for the higher-dose denosumab product Xgeva (120 mg), not Prolia (60 mg). Do not confuse these two products in your PA paperwork. GHC reviewers will reject a PA for Prolia submitted with bone-metastasis cancer documentation if the correct product for that indication is Xgeva.

How to Submit a Prior Authorization That Gets Approved the First Time

Incomplete PA submissions are the single most common reason for initial denial. A complete file typically includes:

1. The completed GHC/carrier-specific PA form with ICD-10 codes (M81.0 for age-related osteoporosis in women without fracture; M80.00XA for osteoporosis with current fracture; Z79.52 for long-term glucocorticoid use).
2. The most recent DXA report with T-scores and the scan date (results older than 24 months may not satisfy requirements).
3. A detailed clinical note from the prescriber documenting diagnosis, fracture history or risk calculation, bisphosphonate trial dates and outcomes, and rationale for Prolia.
4. Any specialist consultation notes.
5. A letter of medical necessity that explicitly maps each PA criterion to the patient's clinical record.

The HealthRX Clinical Coverage Framework for Prolia PA submissions recommends structuring the letter of medical necessity in the same order as the plan's PA criteria checklist, with each criterion followed by a corresponding record excerpt. Reviewers process dozens of files daily. A document that mirrors their checklist cuts processing time and reduces the chance of an administrative denial for "incomplete information."

Submit the PA through the prescriber's office, not directly from the pharmacy. The PA must be approved before the first injection is administered. Retroactive authorization for Prolia is almost never granted because it is classified as a non-emergency elective treatment.

What to Do When GHC Denies Coverage for Prolia

A denial is not the end. Federal and state law provide multiple layers of appeal for health plan denials.

Level 1 internal appeal. You have the right to an internal appeal within the plan. Submit within the plan's deadline (typically 180 days from denial notice under ACA rules). Include new clinical documentation not in the original file: updated DXA results, a fracture risk calculator printout (available free at sheffield.ac.uk/FRAX), the AACE 2022 guideline excerpt, and a written statement from the treating physician.

Peer-to-peer review. Before or during the appeal, your prescriber may request a peer-to-peer call with the plan's medical reviewer. This is often more efficient than a written appeal alone. Studies examining managed-care prior authorization show that peer-to-peer contact overturns a substantial proportion of initial specialty-drug denials [8].

Level 2 external review. If the internal appeal fails, the plan must offer an Independent Review Organization (IRO) review. IRO reviewers are board-certified clinicians with no financial relationship to the plan. The IRO decision is binding on the plan under ACA Section 2719.

State insurance commissioner complaint. Washington State, where Group Health Cooperative originated, maintains the Office of the Insurance Commissioner (OIC). Filing a complaint triggers OIC review of the denial and often prompts the plan to reconsider without waiting for the full IRO process.

Medicare patients. If you are on Medicare and enrolled in a GHC Medicare Advantage plan, the appeals pathway is governed by the Centers for Medicare and Medicaid Services (CMS). Request a Coverage Determination, then a Redetermination, then a Reconsideration by a Qualified Independent Contractor (QIC), and finally an Administrative Law Judge hearing if necessary. CMS timelines are strict: standard redetermination must be resolved within 60 days [9].

Prolia Under GHC Medicare Advantage Plans

Medicare Part B covers Prolia when it is administered in a physician's office or outpatient hospital setting, because it is a physician-administered drug. Under Medicare Part B, cost-sharing is typically 20% of the Medicare-approved amount after the Part B deductible ($240 in 2024) is met [10].

GHC Medicare Advantage plans may alter that cost-sharing through their plan benefit structure. Some GHC Medicare Advantage variants set a fixed specialist visit copay for the injection day rather than 20% coinsurance, which benefits patients on high-cost biologics. Check the plan's Annual Notice of Change for the benefit year you are in, because Medicare Advantage plans can change benefit structures each October 15 for the following January.

The Medicare Coverage of Osteoporosis Drugs provision under Social Security Act Section 1861(kk) covers injectable osteoporosis drugs for beneficiaries who have a fracture related to postmenopausal osteoporosis, are unable to self-administer the drug, and have a physician certification of need [11]. This provision may allow coverage even when the standard Medicare Advantage formulary criteria have not been met, and it is frequently overlooked by both patients and plan representatives.

Comparing Prolia to Covered Alternatives When Authorization Is Denied

If Prolia authorization is ultimately denied after exhausting appeals, your prescriber should review the full formulary for covered alternatives. The agents below are typically available at lower tiers on GHC formularies:

Alendronate (generic Fosamax), 70 mg weekly oral. Tier 1 generic, cost under $15/month. The FLEX trial (N=1,099) showed sustained fracture risk reduction up to 10 years of use [12]. For patients who cannot tolerate weekly tablets, 10 mg daily is an alternative.

Risedronate (generic Actonel), 35 mg weekly or 150 mg monthly oral. Similar tier placement to alendronate. Monthly dosing may improve adherence for some patients.

Zoledronic acid (generic Reclast), 5 mg IV once yearly. Administered as a 15-minute infusion. The HORIZON trial (N=7,765) showed a 70% reduction in vertebral fracture and a 41% reduction in hip fracture at 3 years [13]. IV administration bypasses GI intolerance concerns that disqualify alendronate.

Raloxifene (Evista, generic available), 60 mg daily oral. A selective estrogen receptor modulator. The MORE trial (N=7,705) showed a 36-55% reduction in vertebral fracture at 3 years, though it does not significantly reduce hip fracture risk [14].

Teriparatide (Forteo) or abaloparatide (Tymlos). Anabolic agents typically require their own PA process and have higher cost-sharing than bisphosphonates, but they are sometimes approved when bisphosphonate failure is documented and Prolia is denied.

The clinical decision between these agents should be made by a clinician, not by a formulary tier. If bisphosphonate contraindications exist and Prolia remains denied, zoledronic acid often satisfies both the clinical need and a revised PA argument, because it avoids the GI exposure that oral bisphosphonates carry.

Bone Health Monitoring Requirements That Support Ongoing Coverage Approval

Prolia requires clinical monitoring that, if documented properly, supports renewal PA approvals and demonstrates medical necessity to any reviewer.

Serum calcium and 25-hydroxyvitamin D should be checked before each injection. Prolia carries an FDA black-box warning for hypocalcemia, which can be severe and life-threatening. Correcting vitamin D deficiency before initiation is a labeled requirement [1]. Most GHC plans will flag renewal PA requests for a calcium result dated within 90 days of the renewal request.

DXA every 1-2 years confirms BMD response. The Endocrine Society's 2019 Pharmacological Management of Osteoporosis guideline states: "Patients treated with denosumab should have BMD measured every 1-2 years to assess response." [15] A DXA showing stable or improving T-score is compelling evidence for renewal authorization.

Discontinuation of Prolia without transitioning to a bisphosphonate carries a documented rebound fracture risk. The Journal of Bone and Mineral Research published data showing vertebral fracture rates as high as 7.1% in the 12 months following Prolia discontinuation without subsequent antiresorptive therapy [16]. If a plan declines renewal, your prescriber should document this risk explicitly in the renewal appeal, because allowing a coverage gap in denosumab treatment is clinically dangerous, not merely inconvenient.

After stopping Prolia, transition to zoledronic acid 5 mg IV, given 6 months after the last Prolia injection, is the standard clinical approach supported by current guidelines to prevent rebound bone loss [15].